Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Working Capital Changes (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other Working Capital Changes for 16 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes changed N/A to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.9 million for FY2025, 20.3% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $2.9 million at Cytokinetics, up from -$2.1 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $24.1 million in Q2 2021, with the low at -$29.8 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is -$71470.6, with a median of $522000.0 recorded in 2022.
  • The sharpest move saw Other Working Capital Changes soared 1954.61% in 2021, then crashed 1053.45% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$29.8 million in 2021, then soared by 56.4% to -$13.0 million in 2022, then skyrocketed by 89.82% to -$1.3 million in 2023, then soared by 215.63% to $1.5 million in 2024, then surged by 91.57% to $2.9 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $2.9 million, -$2.1 million, and $1.5 million for Q4 2025, Q1 2025, and Q3 2024 respectively.